Back to all papers

Automatic Quantification of Ki-67 Labeling Index in Pediatric Brain Tumors Using QuPath

May 12, 2025medrxiv logopreprint

Authors

Spyretos, C.,Pardo Ladino, J. M.,Blomstrand, H.,Nyman, P.,Snodahl, O.,Shamikh, A.,Elander, N. O.,Haj-Hosseini, N.

Affiliations (1)

  • Department of Biomedical Engineering, Linkoping University, Sweden

Abstract

AO_SCPLOWBSTRACTC_SCPLOWThe quantification of the Ki-67 labeling index (LI) is critical for assessing tumor proliferation and prognosis in tumors, yet manual scoring remains a common practice. This study presents an automated workflow for Ki-67 scoring in whole slide images (WSIs) using an Apache Groovy code script for QuPath, complemented by a Python-based post-processing script, providing cell density maps and summary tables. The tissue and cell segmentation are performed using StarDist, a deep learning model, and adaptive thresholding to classify Ki-67 positive and negative nuclei. The pipeline was applied to a cohort of 632 pediatric brain tumor cases with 734 Ki-67-stained WSIs from the Childrens Brain Tumor Network. Medulloblastoma showed the highest Ki-67 LI (median: 19.84), followed by atypical teratoid rhabdoid tumor (median: 19.36). Moderate values were observed in brainstem glioma-diffuse intrinsic pontine glioma (median: 11.50), high-grade glioma (grades 3 & 4) (median: 9.50), and ependymoma (median: 5.88). Lower indices were found in meningioma (median: 1.84), while the lowest were seen in low-grade glioma (grades 1 & 2) (median: 0.85), dysembryoplastic neuroepithelial tumor (median: 0.63), and ganglioglioma (median: 0.50). The results aligned with the consensus of the oncology, demonstrating a significant correlation in Ki-67 LI across most of the tumor families/types, with high malignancy tumors showing the highest proliferation indices and lower malignancy tumors exhibiting lower Ki-67 LI. The automated approach facilitates the assessment of large amounts of Ki-67 WSIs in research settings.

Topics

pathology

Ready to Sharpen Your Edge?

Subscribe to join 7,600+ peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.